Vaccine Ligand Binding Assay Life Cycle Management, Assay Maintenance, Monitoring and Transfer.

Area of Science:

• Bioanalytical Science
• Vaccinology
• Regulatory Science

Background:

• Ligand Binding Assays (LBAs) are crucial for vaccine immunogenicity studies.
• Existing guidelines (e.g., ICH-M10) primarily address chemical/biological drugs, not vaccine assays.
• The Workshop on Recent Issues in Bioanalysis (WRIB) identified a need for harmonized vaccine assay validation.

Purpose of the Study:

• To provide recommendations for the lifecycle management of LBAs used in vaccine immunogenicity studies.
• To address the maintenance, monitoring, and transfer of LBAs post-validation.
• To help close the regulatory gap for vaccine assay validation.

Main Methods:

• Development of a white paper through a collaborative working group of 16 global companies and regulators.
• Leveraging discussions and consensus from previous WRIB White Papers (2017-2020).
• Focusing on Part 3 of a series, specifically on LBA lifecycle management.

Main Results:

• Detailed discussion of activities ensuring consistent assay performance after validation.
• Identification of specific needs for LBA maintenance, monitoring, and transfer.
• Establishment of a framework to support vaccine development through harmonized assay validation.

Conclusions:

• This white paper (Part 3) offers guidance on LBA lifecycle management for vaccine immunogenicity.
• Harmonization efforts aim to improve consistency and reliability of vaccine immunogenicity data.
• The collective white papers will be pivotal for the entire vaccine development process.